Author

M. A. Rubin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 8

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 8 Assay:bulk RNA-seq· 7 Research Focus:differential expression· 6 Research Focus:cell type annotation· 5 Approach:statistical model· 5 Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Research Focus:cancer & tumor microenvironment· 2

Frequent Co-Authors

S. Piscuoglio· 5 shared C. K. Ng· 3 shared J. Gallon· 3 shared M. Bolis· 3 shared Y. Chen· 3 shared A. Califano· 2 shared A. Garofoli· 2 shared A. Vasciaveo· 2 shared

Activity by Year

2018-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

S. Piscuoglio

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader molecules

P. D. Thienger, I. Paassen, X. Yao, P. D. Rubin, M. Lehner, N. Lillis, A. Benjak, S. Shah, A. King-Yung Leung, S. de Brot, A. Naveed, B. Daniel, M. Shi, J. Tremblay, J. Triscott, , M. A. Rubin

This study identifies a SWI/SNF-targeting therapy effective against a double-negative prostate cancer subtype, showing it reduces viability in both AR-dependent and WNT-dependent models.

bioRxiv · Mar 24, 2024Cancer Biology

NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer

J. J. Li, A. Vasciaveo, D. Karagiannis, Z. Sun, X. Chen, F. Socciarelli, Z. Frankenstein, M. Zou, T. Pannellini, Y. Chen, K. Gardner, B. D. Robinson, J. de Bono, C. Abate-Shen, M. A. Rubin, , M. M. Shen

This study identifies NSD2 as a key driver of lineage plasticity and castration-resistance in neuroendocrine prostate cancer, showing its inhibition can restore sensitivity to AR inhibitors.

bioRxiv · Jul 18, 2023 · PreprintCancer Biology

OncoLoop: A network-based precision cancer medicine framework

A. Vasciaveo, M. Zou, J. M. Arriaga, F. Geraldes de Almeida, E. F. Douglass, M. Shibata, A. Rodriguez-Calero, S. de Brot, A. Mitrofanova, C. W. Chua, C. Karan, R. Realubit, S. Y. Pampou, J. Y. Kim, E. Corey, , C. Abate-Shen

OncoLoop predicts and validates drug sensitivity in tumors and their models by leveraging perturbational profiles of oncology drugs, showing success in prostate cancer models and patient cohorts.

bioRxiv · Feb 11, 2022Cancer Biology

Minor intron splicing efficiency increases with the development of lethal prostate cancer

A. Augspach, K. Drake, L. Roma, E. Qian, S. R. Lee, D. Clarke, S. Kumar, M. Jaquet, J. Gallon, M. Bolis, J. Triscott, J. A. Galvan, Y. Chen, G. Thalmann, M. Kruithof-de Julio, , M. A. Rubin

The paper shows that minor intron splicing efficiency increases in castration-resistant prostate cancer and that inhibiting the minor spliceosome reduces tumor burden.

bioRxiv · Dec 9, 2021 · PreprintCancer Biology

Patient-derived xenografts and organoids model therapy response in prostate cancer

S. Karkampouna, F. La Manna, M. R. De Filippo, M. Kiener, M. De Menna, E. Zoni, J. Grosjean, I. Klima, A. Garofoli, M. Bolis, J.-P. Theurillat, V. Genitsch, D. Keller, T. Booij, C. Stirnimann, , M. Kruithof-de Julio

This study develops a patient-derived xenograft (PDX) model of prostate cancer that mimics disease stages and identifies drug sensitivities in metastatic cases.

Nature Communications · Feb 18, 2021Peer-reviewedCancer Biology

Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance

K. A. Cotter, J. Gallon, N. Uebersax, P. Rubin, K. D. Meyer, S. Piscuoglio, S. R. Jaffrey, M. A. Rubin

The paper maps m6A in prostate cancer and shows METTL3-low promotes therapy resistance through upregulated extracellular matrix proteins and hepatocyte nuclear factor-driven gene signatures.

bioRxiv · Jan 12, 2021Cancer Biology

The Genomic Landscape of Prostate Cancer Brain Metastases

A. Rodriguez, J. Gallon, D. Akhoundova, S. Maletti, A. Ferguson, J. Cyrta, U. Amstutz, A. Garofoli, V. Paradiso, S. Tomlins, E. Hewer, V. Genitsch, A. Fleischmann, E. J. Rushing, R. Grobholz, , M. A. Rubin

This study identifies genomic alterations in prostate cancer brain metastases, highlighting mutations in NF1 and RICTOR and DNA homologous repair defects as potential drivers.

bioRxiv · May 12, 2020 · PreprintCancer Biology

Proteomic and Genomic Signatures of Repeat-instability in Cancer and Adjacent Normal Tissues

E. Persi, D. Prandi, Y. I. Wolf, Y. Pozniak, C. Barbieri, P. Gasperini, H. Beltran, B. M. Faltas, M. A. Rubin, T. Geiger, E. V. Koonin, F. Demichelis, D. Horn

The paper quantifies repeat-instability in cancer and normal tissues using proteomic and genomic data, identifying tumor-specific signatures linked to progression and tumorigenic state.

bioRxiv · Dec 9, 2018Cancer Biology